News

Alcon Sees Surge in Shares Following Positive Results for Dry-Eye Treatment

1 Mins read

Swiss pharmaceutical company Alcon experienced a notable rise in shares on Wednesday after announcing positive results for its dry-eye disease treatment in two trials.

At 0834 GMT, Swiss shares of Alcon were up 4.8% at CHF69.46, reaching a high of CHF70.20.

Alcon confirmed on Tuesday that its candidate drug, AR-15512, successfully achieved its primary goals with statistical significance in treating dry-eye disease. The company plans to submit a new drug application to the U.S. Food and Drug Administration by mid-2024.

According to a research note by Citi analysts, the drug has demonstrated faster efficacy compared to its competitors Restasis and Xiidra, positioning it for a substantial market share in the United States. Analysts project an estimated earnings-per-share increase of approximately 3% for every $100 million in sales by 2026. The U.S. dry-eye treatment market, where Alcon is listed, is valued between $1.5 billion and $2 billion, as stated by Citi.

Additionally, Alcon successfully met secondary goals, including the promotion of rapid and sustained tear production.

Related posts
News

Tron Inc. Debuts on Nasdaq as Justin Sun Rings Opening Bell - TokenPost

1 Mins read
Tron Inc., the largest holder of TRX, has achieved a major milestone by officially listing on the Nasdaq exchange, marking a historic…
News

EFCC Takes Sensitization Campaign On Virtual Assets, Money Laundering To CBN - InfoStride News

2 Mins read
Operatives of the Benin Zonal Directorate of the Economic and Financial Crimes Commission, EFCC, on Thursday, July 24, sensitized officers of Central…
News

Binance's Top Trending Cryptocurrency Picks for Today, July 23, 2025

10 Mins read
Looking for what’s hot in crypto today, July 23, 2025? We’ve got the rundown on the top trending cryptocurrency picks you’ll find…

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 1 = 10